Zepp Health (ZEPP) Form 144/A: 11,000 ADRs Proposed Sale ($411K)
Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding.
Rhea-AI Filing Summary
Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding. The proposed approximate date of sale is 09/04/2025 on the NYSE. The ADRs to be sold were acquired on 02/12/2018 through vesting of a restricted stock award from Zepp Health Corporation; the original grant comprised 25,000 shares and payment was recorded as vesting of a restricted share award on the same date. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR Proposed sale of 11,000 ADRs valued at $411,070 is disclosed; transaction originates from a 2018 restricted stock vesting.
The filing documents a routine Section 144 notice for an insider or affiliate planning to sell 11,000 ADRs on the NYSE with an approximate sale date of 09/04/2025. The securities were acquired via vesting on 02/12/2018
From an investor-impact perspective, the size of the proposed sale ($411k) appears modest relative to typical market capitalizations for exchange-listed issuers, and the filer reports no sales in the prior three months. The Form contains the required attestation about absence of undisclosed material information. No earnings, debt, or operational data are provided in this filing.
TL;DR This is a compliance disclosure of an intended sale under Rule 144 tied to vested restricted shares; it follows required attestation language.
The notice records the origin of the shares as a restricted stock vesting event in 2018 and states the filer has not sold related securities in the prior three months. The filing includes the standard Rule 10b5-1/attestation language, but does not indicate a trading plan adoption date. For governance reviews, the document is a routine disclosure and contains no additional corporate actions or governance changes.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What securities does Zepp Health (ZEPP) plan to sell according to this Form 144/A?
When is the approximate sale date listed on the Form 144/A for ZEPP?
How and when were the securities being sold originally acquired?
Were any ZEPP securities sold by the filer in the past three months?
On which exchange is the proposed sale to occur?
AI-generated analysis. How Rhea-AI works. Not financial advice.